An updated position statement on the management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer provides the latest evidence-based guidance, with an ...
An updated joint position statement on the management of aromatase inhibitor-associated bone loss (AIBL) addresses the heightened fracture risk in women undergoing endocrine therapy for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results